ABSTRACTS: 3000 and 3005
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety profiles in heavily pretreated patients with advanced solid tumors. The studies were featured in an oral abstract session highlighting the development of new molecularly targeted...
ABSTRACTS: 6504, 6507
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two...
In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center will...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features presentations by MD Anderson researchers at the 2024 American Society...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
For most smokers, quitting on the first attempt is likely to be unsuccessful, but a new study from The University of Texas MD Anderson Cancer...
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been...
The University of Texas MD Anderson Cancer Center and the Pan American Health Organization (PAHO) today announced the signing of an agreement...